Customize your JAMA Network experience by selecting one or more topics from the list below.
GEORGE J.HRUZAMDMICHAEL P.HEFFERNANMDSUMMER R.YOUKERMD
Patient 1 is a 42-year-old white man who has had alopecia areata (AA) for 17 years. His father also has extensive AA. Early in the course of the disease, the patient intermittently received prednisone, 15 to 30 mg/d for 2 years, with 1 year being the longest duration of continuous treatment followed by an additional 7-month taper. The patient also received topical fluocinolone acetonide 0.1% (Synalar; Medicis, Scottsdale, Ariz) solution and intralesional triamcinolone acetonide (Kenalog; Bristol-Myers-Squibb, New York, NY) injections for most of the duration of the disease. He typically receives intralesional triamcinolone, 10 mg/mL to his scalp and 3 to 5 mg/mL to his eyebrows, every 4 to 10 weeks. Intralesional triamcinolone was helpful, with remissions lasting 2 months. Sulfasalazine administered failed secondary to drug eruption. He has never received contact sensitizers.
Heffernan MP, Hurley MY, Martin KS, Smith DI, Anadkat MJ. Alefacept for Alopecia Areata. Arch Dermatol. 2005;141(12):1513–1516. doi:10.1001/archderm.141.12.1513
Create a personal account or sign in to: